Clinical Trial Update: Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC [Phase 2, Phase 3]

View source ↗

Summary

Phase 2 and Phase 3 clinical trials evaluating EVOZAC Calming Skin Spray to prevent EGFR-TKI–associated rash in non-small cell lung cancer have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EVOZAC Calming Skin Spray

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: COMPLETED